Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q4 FY20 results · Jan–Mar 2020
Divi's Laboratories reported revenue from operations of ₹1,389.71 crore and net profit of ₹388.23 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,389.71 | 0.00 | — | 1,396.26 | −0.5% |
| Other income | 76.73 | 0.00 | — | 41.67 | +84.1% |
| Total income | 1,466.44 | 0.00 | — | 1,437.93 | +2.0% |
| Profit before tax | 470.96 | 0.00 | — | 487.32 | −3.4% |
| Net profit for the period | 388.23 | 0.00 | — | 359.09 | +8.1% |
| EPS, basic (₹) | 14.62 | 0.00 | — | 13.53 | +8.1% |
| Net margin (%) | 27.9 | — | 25.7 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,376.24 | 1,256.43 | +9.5% | 1,390.49 | −1.0% |
| Other income | 76.52 | 41.73 | +83.4% | 40.31 | +89.8% |
| Total income | 1,452.76 | 1,298.16 | +11.9% | 1,430.80 | +1.5% |
| Profit before tax | 475.22 | 410.38 | +15.8% | 488.94 | −2.8% |
| Net profit for the period | 391.80 | 289.35 | +35.4% | 360.73 | +8.6% |
| EPS, basic (₹) | 14.76 | 10.90 | +35.4% | 13.59 | +8.6% |
| Net margin (%) | 28.5 | 23.0 | 25.9 |
Consolidated
- Filed with BSE
- 06 Jun 2020, 17:24 IST
- Board meeting
- 06 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Jun 2020, 17:24 IST
- Board meeting
- 06 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE